Newport Laboratories announced the addition of MAINSAIL, a Mycoplasma hyopneumoniae bacterin, to its swine commercial product portfolio.
MAINSAIL, manufactured by ProtaTek International Inc. in St. Paul, Minn., is a single-dose M. hyopneumoniae bacterin manufactured with a novel dual-adjuvant system. MAINSAIL is for use in healthy pigs of all breeds, three weeks of age or older as an aid in the reduction of lung lesions due to swine enzootic pneumonia caused by M. hyopneumoniae. A 1.0 mL dose administered intramuscularly offers at least 194 days duration of immunity, Newport Labs said.
MAINSAIL features a single, 1.0 mL dose volume reducing handling time and animal stress while minimizing tissue disruption. MAINSAIL is available in 100-, 250- and 500-dose sizes. Swine practitioners can purchase MAINSAIL directly from Newport Laboratories. Swine producers are encouraged to speak with their veterinarian for details and purchasing information.